Traverse 2024 Testosterone. A phase 4 trial of men with hypogonadism in the us offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy. Recently papers from the traverse trial addressing cardiovascular safety,1 effects on prostate6 and bone,7 anaemia,8 depression,9 somatic symptoms and sexual function10.


Traverse 2024 Testosterone

Testosterone replacement therapy was not associated with an increase in major adverse cardiovascular events compared with placebo in the large traverse study of middle. The traverse study was mandated by the us food and drug administration in 2015 in response to concerns and conflicting data regarding the cardiovascular safety of.

Traverse 2024 Testosterone Images References :